Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

AstraZeneca holds FTSE back, Carillion loses last 'buy' rating

07/13/2017 | 12:06pm EST
People walk through the lobby of the London Stock Exchange in London

LONDON (Reuters) - British shares underperformed in Europe on Thursday, with AstraZeneca weighing on the healthcare sector and BP (>> BP) and Royal Dutch Shell tracking crude prices lower.

LONDON (Reuters) - British shares underperformed in Europe on Thursday, with AstraZeneca weighing on the healthcare sector and BP (>> BP) and Royal Dutch Shell <RDSa.L> tracking crude prices lower.

Retailers and BT (>> BT Group) made gains but the FTSE 100 <.FTSE> ended the session 0.1 percent lower at 7,413.44 points, lagging Europe's 0.4 percent rise.

Troubled construction services company Carillion (>> Carillion), which has seen 70 percent of its market value wiped out since a profit warning and the exit of its CEO on Monday, slipped another 3.1 percent in choppy trading as JPMorgan slashed its "overweight" rating to "neutral".

Investors shunned AstraZeneca (>> AstraZeneca) shares, which slid 3.4 percent to the bottom of the FTSE after a media report said Chief Executive Pascal Soriot could be preparing to defect to Israel-based Teva Pharmaceutical Industries (>> Teva Pharmaceutical Industries Limited). The company declined to deny the report.

Some analysts questioned whether reports of a move suggested the results of the company's MYSTIC trial of a lung cancer candidate could fail - although others said they saw no link.

"We find it hard to believe a Soriot departure would have direct read-across to (key lung cancer trial) Mystic, and would favour remuneration and the UK mood music as at least a key part of the explanation," said Liberum analyst Roger Franklin.

"Any significant fall today could therefore be a buying opportunity for long-term investors," he added.

BT led blue-chip gainers and Europe's telecoms sector <.SXKP>, up 4 percent after UK broker Numis started covering the company with a "buy" rating.

"Earlier this year the company and (regulator) Ofcom gave many BT shareholders much heartache, but at current levels we believe the share price discounts some incredible assumptions," Numis analysts wrote.

Retailers Marks & Spencer (>> Marks & Spencer Group) and Next (>> Next) made solid gains, as investors read across from stronger results reported by French supermarket Casino (>> Casino Guichard-Perrachon), lifting retailers across Europe <.SXRP>.

N Brown (>> N Brown Group plc) slid 6.5 percent, the worst mid-cap faller, after the plus-size fashion retailer said it would incur an exceptional charge of up to 40 million pounds ($52 million) for potential customer redress on flaws in products sold between 2006 and 2014.

Ocado (>> Ocado Group PLC) gained 2.4 percent, however, after Credit Suisse raised its target price on the stock, predicting the online grocer would expand margins through automation.

"Whereas we think the market has tended to view Ocado's latest-generation facility as the endpoint of the investment case, we believe this platform will allow Ocado to drive widespread automation and monetise its intellectual property," analysts at the Swiss bank wrote.

Barclays said fears of the impact on housebuilders from potential interest rate rises were "overblown", upping its ratings on some firms.

(Reporting by Helen Reid and Kit Rees; Editing by Alison Williams)

By Helen Reid and Kit Rees

© Reuters 2017
Stocks mentioned in the article
ChangeLast1st jan.
AMP LIMITED 0.00% 1.73 End-of-day quote.-9.66%
ASTRAZENECA PLC -0.74% 7682 Delayed Quote.1.85%
BP PLC -1.32% 260.7 Delayed Quote.-44.13%
BT GROUP PLC -0.09% 122.1899 Delayed Quote.-36.45%
CARILLION 0.00% 14.2 Delayed Quote.0.00%
CASINO, GUICHARD-PERRACHON -0.45% 24.34 Real-time Quote.-41.30%
MARKS & SPENCER GROUP PLC -1.84% 127.7758 Delayed Quote.-39.02%
MSCI UNITED KINGDOM (STRD, UHD) -0.88% 992.939 Real-time Quote.-15.86%
N BROWN GROUP PLC -0.72% 58.177 Delayed Quote.-64.00%
NEXT PLC -1.22% 6497.36 Delayed Quote.-6.30%
OCADO GROUP PLC -0.64% 2180.555 Delayed Quote.71.46%
RISE, INC. 4.17% 25 End-of-day quote.-16.67%
SWISS RE LTD -0.76% 83.44 Delayed Quote.-22.63%
All news about ASTRAZENECA PLC
04:58aWRAPUP 1-Britain presses on with AstraZeneca vaccine amid questions over tria..
04:15aPhilippines secures 2.6 mln doses of AstraZeneca's COVID-19 vaccine
04:10aDollar edges down, set for weekly loss; Aussie and Kiwi rise
04:08aAstraZeneca CEO expects to run new global trial of COVID-19 vaccine - Bloombe..
04:08aASTRAZENECA : says working with regulators on best approach to lower dose regime..
04:03aDollar edges down, set for weekly loss; Aussie and Kiwi rise
03:39aEuropean stocks set for fourth weekly gain but vaccine worries weigh
03:37aVaccine developer SK Bioscience targets IPO in first half of 2021
03:33aUK shares poised for weekly loss on vaccine doubts, Brexit concerns
03:15aGold on track for weekly fall as investors overlook vaccine doubts
More news
Financials (USD)
Sales 2020 26 512 M - -
Net income 2020 2 998 M - -
Net Debt 2020 13 181 M - -
P/E ratio 2020 46,6x
Yield 2020 2,72%
Capitalization 136 B 136 B -
EV / Sales 2020 5,62x
EV / Sales 2021 4,89x
Nbr of Employees 70 600
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 121,48 $
Last Close Price 103,46 $
Spread / Highest target 50,3%
Spread / Average Target 17,4%
Spread / Lowest Target -36,2%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-1.50%378 244
ROCHE HOLDING AG-3.47%285 939
NOVARTIS AG-11.58%203 854
PFIZER INC.-1.59%203 048
MERCK & CO., INC.-11.97%202 555